[ CAS No. 7536-58-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 7536-58-5 * Storage: {[proInfo.prStorage]}

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	Inquiry	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]}	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]}	{[ item.pr_usastock ]}		{[ item.pr_chinastock ]}	{[ item.pr_remark ]}	Login		Inquiry

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 7536-58-5 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 7536-58-5 ]

SDS Specification

Alternatived Products of [ 7536-58-5 ]

Product Citations

N-Succinylaspartic-Acid-Conjugated Riluzole Is a Safe and Potent Colon-Targeted Prodrug of Riluzole against DNBS-Induced Rat Colitis

Kim, Jaejeong ; Kang, Changyu ; Yoo, Jin-Wook , et al. Pharmaceutics,2023,15(11):2638. DOI: 10.3390/pharmaceutics15112638 PubMed ID: 38004616

Abstract: In our previous study, riluzole azo-linked to salicylic acid (RAS) was prepared as a colon-targeted prodrug of riluzole (RLZ) to facilitate the repositioning of RLZ as an anticolitic drug. RAS is more effective against rat colitis than RLZ and sulfasalazine, currently used as an anti-inflammatory bowel disease drug. The aim of this study is to further improve colon specificity, anticolitic potency, and safety of RAS. N-succinylaspart-1-ylRLZ (SAR) and N-succinylglutam-1-ylRLZ (SGR) were synthesized and evaluated as a ""me-better"" colon-targeted prodrug of RLZ against rat colitis. SAR but not SGR was converted to RLZ in the cecal contents, whereas both conjugates remained intact in the small intestine. When comparing the colon specificity of SAR with that of RAS, the distribution coefficient and cell permeability of SAR were lower than those of RAS. In parallel, oral SAR delivered a greater amount of RLZ to the cecum of rats than oral RAS. In a DNBS-induced rat model of colitis, oral SAR mitigated colonic damage and inflammation and was more potent than oral RAS. Moreover, upon oral administration, SAR had a greater ability to limit the systemic absorption of RLZ than RAS, indicating a reduced risk of systemic side effects of SAR. Taken together, SAR may be a "me-better" colon-targeted prodrug of RLZ to improve the safety and anticolitic potency of RAS, an azo-type colon-targeted prodrug of RLZ.

Keywords: riluzole ; colon-targeted drug delivery ; colitis ; prodrug ; N-succinylated acidic amino acids

Purchased from AmBeed: 13574-13-5 ; 7536-58-5 ; 1744-22-5 ; 530-62-1

Product Details of [ 7536-58-5 ]

CAS No. :	7536-58-5	MDL No. :	MFCD00065564
Formula :	C₁₆H₂₁NO₆	Boiling Point :	No data available
Linear Structure Formula :	C₄H₇NO₄C₅H₈O₂C₇H₆	InChI Key :	SOHLZANWVLCPHK-LBPRGKRZSA-N
M.W :	323.34	Pubchem ID :	1581888
Synonyms :

Calculated chemistry of [ 7536-58-5 ] Expand+

Physicochemical Properties

Num. heavy atoms :	23
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.44
Num. rotatable bonds :	10
Num. H-bond acceptors :	6.0
Num. H-bond donors :	2.0
Molar Refractivity :	82.24
TPSA :	101.93 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	Yes
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.94 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.19
Log Po/w (XLOGP3) :	1.88
Log Po/w (WLOGP) :	1.95
Log Po/w (MLOGP) :	1.59
Log Po/w (SILICOS-IT) :	1.58
Consensus Log Po/w :	1.84

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.56

Water Solubility

Log S (ESOL) :	-2.56
Solubility :	0.886 mg/ml ; 0.00274 mol/l
Class :	Soluble
Log S (Ali) :	-3.64
Solubility :	0.0736 mg/ml ; 0.000228 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-3.25
Solubility :	0.183 mg/ml ; 0.000566 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	3.32

Safety of [ 7536-58-5 ]

Signal Word:	Warning	Class:
Precautionary Statements:	P280-P305+P351+P338	UN#:
Hazard Statements:	H302	Packing Group:
GHS Pictogram:

Application In Synthesis of [ 7536-58-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 7536-58-5 ]
Downstream synthetic route of [ 7536-58-5 ]

[ 7536-58-5 ] Synthesis Path-Upstream 1~1

1
[ 7536-58-5 ]
[ 6327-59-9 ]

Reference： [1] Journal of Organic Chemistry, 1993, vol. 58, # 9, p. 2369 - 2376

[ 7536-58-5 ] Synthesis Path-Downstream 1~8

1
[ 7536-58-5 ]
[ 2886-33-1 ]
[ 104870-31-7 ]

Reference： [1]Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry,1988,vol. 27,p. 405 - 408
[2]Journal of Medicinal Chemistry,1990,vol. 33,p. 2734 - 2744

2
[ 2886-33-1 ]
[ 7536-58-5 ]

Reference： [1]Journal of Organic Chemistry,1993,vol. 58,p. 2369 - 2376

3
[ 15761-38-3 ]
[ 7536-58-5 ]
[ 13726-85-7 ]
[ 15260-10-3 ]
[ 13836-37-8 ]
[ 61925-77-7 ]
[ 54613-99-9 ]
[ 40350-83-2 ]
RDCCTOOKKCKDKQCKOQRCCA-NH₂, containing three disulfide bonds between Cys3 and Cys15, Cys4 and Cys20, Cys10 and Cys21, O: 4-trans-hydroxyproline [ No CAS ]